<code id='737C4D2142'></code><style id='737C4D2142'></style>
    • <acronym id='737C4D2142'></acronym>
      <center id='737C4D2142'><center id='737C4D2142'><tfoot id='737C4D2142'></tfoot></center><abbr id='737C4D2142'><dir id='737C4D2142'><tfoot id='737C4D2142'></tfoot><noframes id='737C4D2142'>

    • <optgroup id='737C4D2142'><strike id='737C4D2142'><sup id='737C4D2142'></sup></strike><code id='737C4D2142'></code></optgroup>
        1. <b id='737C4D2142'><label id='737C4D2142'><select id='737C4D2142'><dt id='737C4D2142'><span id='737C4D2142'></span></dt></select></label></b><u id='737C4D2142'></u>
          <i id='737C4D2142'><strike id='737C4D2142'><tt id='737C4D2142'><pre id='737C4D2142'></pre></tt></strike></i>

          Home / entertainment / focus

          focus


          focus

          author:knowledge    Page View:46769
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In